問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間:2023-09-19

王舒儀
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

62Cases

2025-07-01 - 2030-12-31

Active
A phase III, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy of AZD0780 in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk of first ASCVD events for major adverse cardiovascular events.
  • Condition/Disease

    Patients with established atherosclerotic cardiovascular disease or at high risk of their first atherosclerotic cardiovascular event.

  • Test Drug

    AZD0780

Participate Sites
23Sites

Recruiting23Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2008-09-01 - 2010-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2006-02-01 - 2007-06-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2011-12-01 - 2012-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting10Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

2026-06-01 - 2031-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites